53.97
3.43 (6.79%)
| Penutupan Terdahulu | 50.54 |
| Buka | 50.88 |
| Jumlah Dagangan | 2,078,263 |
| Purata Dagangan (3B) | 2,145,719 |
| Modal Pasaran | 8,261,921,280 |
| Harga / Pendapatan (P/E TTM) | 18.87 |
| Harga / Pendapatan (P/E Ke hadapan) | 38.02 |
| Harga / Jualan (P/S) | 11.37 |
| Harga / Buku (P/B) | 13.00 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 3 Aug 2026 |
| Margin Keuntungan | 10.13% |
| Margin Operasi (TTM) | 7.13% |
| EPS Cair (TTM) | 0.250 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 90.40% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | -96.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 107.29% |
| Nisbah Semasa (MRQ) | 4.02 |
| Aliran Tunai Operasi (OCF TTM) | -61.02 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -87.64 M |
| Pulangan Atas Aset (ROA TTM) | 7.26% |
| Pulangan Atas Ekuiti (ROE TTM) | 19.70% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | TG Therapeutics, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | -2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 4.0 |
| Purata | -0.25 |
|
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 9.74% |
| % Dimiliki oleh Institusi | 63.22% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |